Introduction
============

Deleted in liver cancer-1 (*DLC-1*) is a potential tumor suppressor gene, which has been isolated from human hepatocellular carcinoma and identified by representational difference analysis. DLC-1 is localized on human chromo-some 8p21.3-22. The full-length cDNA for DLC-1 contains 3,800 bp and encodes a 1,091-amino acid protein that has 86% homology with the rat pl22RhoGAP gene ([@b1-ol-06-02-0521]).

DLC-1 (also known as ARHGAP7 and STARD12) contains three functional domains: The RhoGTPase-activating protein (RhoGAP) domain, the steroidogenic acute regulatory-related lipid transfer (START) domain and the sterile α-motif (SAM) domain ([@b2-ol-06-02-0521],[@b3-ol-06-02-0521]). Studies have demonstrated that the RhoGAP domain is necessary for inhibiting tumor cell growth, as well as for actin fiber and focal adhesion formation ([@b4-ol-06-02-0521]--[@b6-ol-06-02-0521]). RhoGAPs negatively regulate the Rho family of small GTPases, enhancing the hydrolysis of bound GTP to convert Rho proteins to their inactive GDP-bound state ([@b7-ol-06-02-0521],[@b8-ol-06-02-0521]).

DLC-1 mRNA is expressed in the majority of normal human tissues and is downregulated or absent in a number of common types of human cancer, including brain, lung, breast, liver, stomach, colon and prostate cancers. The aberrant expression of DLC-1 is associated with either genomic deletion or promoter hypermethylation ([@b9-ol-06-02-0521]--[@b14-ol-06-02-0521]). Increasing evidence has shown that DLC-1 negatively regulates tumor cell growth and *in vivo* tumorigenicity ([@b15-ol-06-02-0521]--[@b17-ol-06-02-0521]).

However, DLC-1 has been less intensively examined in pancreatic cancer. To obtain further evidence that DLC-1 functions as a tumor suppressor gene, in the present study, a recombinant plasmid (pcDNA3.1/DLC-1) was constructed and transduced into PANC-1 cells, in order to observe the effect of the DLC-1 gene on cell growth and tumorigenicity.

Materials and methods
=====================

Cell line and culture
---------------------

The human pancreatic carcinoma cell line, PANC-1, was obtained from the Shanghai Institute of Biochemistry and Cell Biology (Chinese Academy of Sciences, Shanghai, China). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics at 37°C, in a humidified incubator with 5% CO~2~.

Plasmid construction
--------------------

A 3.4-kb fragment of the full-length coding sequence of the DLC-1 gene was amplified by PCR from human liver PCR-Ready cDNA (Invitrogen, Carlsbad, CA, USA). The primers included *Nhe*I and *Kpn*I linkers. Subsequent to purification and restriction digestion, the PCR product was ligated to the pcDNA3.1(+) vector (Invitrogen). The sequence and orientation of the DLC-1 recombinant were confirmed by DNA sequencing and restriction enzyme digestion.

Cell transfection
-----------------

The cells (10^5^) were seeded into 24-well plates one day prior to transfection. The cells were transfected with 1 *μ*g plasmid DNA in Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions.

RNA extraction and RT-PCR
-------------------------

Total RNA was extracted from cells using TRIzol reagent (Invitrogen). The total RNA (2 *μ*g) was used as a template in the first strand cDNA synthesis using a First-Strand cDNA Synthesis kit (Shinegene, Shanghai, China) according to the manufacturer's instructions. Total RNA (2 *μ*g) was combined with 0.1 *μ*g oligo(dT)~18~ primer and diethylpyrocarbonate (DEPC) H~2~O and preheated at 65°C for 5 min. The mixture was then placed at 20°C for 10 min, then 10 *μ*l 2X First-Strand Buffer and 1 *μ*l RT mix was added for a total volume of 20 *μ*l. The mixture was incubated at 42°C for 50 min, then the reaction was stopped by heating at 90°C for 5 min. The cDNA stock was stored at −20°C. A pair of primers (forward, GGAATAACGGCTCTGTGAA and reverse, TCTCCGACCACTGATTGAC) was used to amplify the 400-bp fragment of DLC-1. As a control, a pair of primers (forward, GTGGACATCCGCAAAGAC and reverse, AAA GGGTGTAACGCAACTAA) was used to amplify the 200-bp fragment of β-actin. PCR was performed using a PTC-200 PCR machine (MJ Research Inc, Waltham, MA, USA). The reaction conditions were as follows: 94°C for 3 min, then 35 cycles of 94°C for 1 min, 55°C for 30 sec and 72°C for 1 min, followed by a final extension step for 10 min at 72°C.

Western blot analysis
---------------------

The cells were harvested and solubilized in cold RIPA buffer. Proteins were resolved by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. DLC-1 was detected by western blotting using mouse anti-human DLC-1 antibody (BD Biosciences, Franklin Lakes, NJ, USA). β-actin staining served as the internal standard for all membranes.

MTT assays
----------

The cells were plated in 96-well microtiter plates at a density of 10^4^ cells/well, then cultured for 48 h and incubated with 20 *μ*l MTT solution (5 mg/ml) for 4 h. The cells were lysed in 150 *μ*l DMSO, and the absorbance at 490 nm was determined with an ELISA plate reader. The absorbance values for the cell lines transfected with pcDNA3.1(+) alone, pcDNA3.1(+)/DLC-1 and the untransfected cells were compared. The entire experiment was performed three times independently.

Preparation of liposome:plasmid complexes
-----------------------------------------

Plasmids were purified using alkaline lysis. Liposomes were composed of 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol in a 1:1 molar ratio, and the dried lipid film was resuspended with 5% dextrose in water. Following the hydration of the lipids, using a bath sonicator, the liposomes were sonicated until clear. The liposomes were then extruded through poly-carbonate membranes and stored at 4°C until use. Prior to injection, the mixture containing liposomes in a 3:1 mass ratio with the plasmid DNA was incubated at room temperature for 20 min.

Tumorigenicity assay
--------------------

The PANC-1 cells (10^7^) were inoculated subcutaneously into the right oxter of four-week-old female Balb/c athymic nude mice. Eight days subsequent to the injection of cells, the mice were randomly divided into three groups: i) The liposome:pcDNA3.1(+)/DLC-1 group; ii) the liposome:pcDNA3.1(+) group; and iii) the isosmotic saline treatment group. Each group contained 10 mice and each mouse received seven intravenous injections via the tail vein, five days apart. Each injection (200 *μ*l) consisted of liposomes (150 *μ*g) complexed to 50 *μ*g of a plasmid encoding DLC-1 or a control plasmid. Tumor size was measured in two dimensions prior to each injection and five days subsequent to the last injection, using a vernier caliper. This study was approved by the ethics committee of West China Hospital, Sichuan University, China.

Statistical analysis
--------------------

Data are expressed as the mean ± SD. All statistical analyses were performed with standard statistical programs (SPSS for Windows, version 17.0; SPSS, Inc., Chicago, IL, USA). A one-way ANOVA was used for the statistical analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Overexpression of the DLC-1 gene by liposome-mediated transfection
------------------------------------------------------------------

Subsequent to 48 h of transfection, the transfection of the DLC-1 gene into the PANC-1 cells was detected by semi-quantitative RT-PCR and western blotting, respectively. As shown in [Figs. 1](#f1-ol-06-02-0521){ref-type="fig"} and [2](#f2-ol-06-02-0521){ref-type="fig"}, a successful transfer of DLC-1 by the liposome complex was demonstrated. In the pcDNA3.1(+)/DLC-1-transfected cells, the mRNA and protein expression levels of DLC-1 were upregulated. By contrast, only weak bands were observed in the empty vector-transfected and untransfected cells.

Overexpression of the DLC-1 gene inhibits cell proliferation
------------------------------------------------------------

To investigate whether DLC-1 was involved in the cell proliferation of PANC-1 cells, an MTT assay was performed subsequent to 48 h of transfection. As shown in [Fig. 3](#f3-ol-06-02-0521){ref-type="fig"}, the OD value was lower in the cells transfected with pcDNA3.1(+)/DLC-1 compared with the cells transfected with the empty vector and the untransfected cells (P\<0.05). The results demonstrated that DLC-1 had an effect on cell proliferation.

Inhibition of in vivo tumorigenicity by the DLC-1 gene
------------------------------------------------------

To investigate the effect of DLC-1 on tumor growth, the liposome:DNA complex was injected into athymic nude mice via the tail vein using pre-established human PANC-1 pancreatic carcinoma cells. As shown in [Fig. 4](#f4-ol-06-02-0521){ref-type="fig"}, the tumors from the liposome:pcDNA3.1(+)/DLC-1 group were smaller than those from the liposome:pcDNA3.1(+) and isosmotic saline treatment groups after the fifth injection (P\<0.05). This result indicates that DLC-1 gene therapy using liposomes as a carrier effectively inhibits tumor growth *in vivo*.

Discussion
==========

In the United States, 42,470 patients were diagnosed with and 35,240 patients succumbed to pancreatic cancer in 2009 ([@b18-ol-06-02-0521]). Pancreatic cancer is the fourth most common cause of cancer-related mortality in the United States. Due to the lack of effective screening modalities, the majority of patients are diagnosed with pancreatic cancer at a regional or distant stage of the disease. The overall five-year relative survival rate for patients with pancreatic cancer is 5% ([@b18-ol-06-02-0521]). At present, surgery is the only curative therapeutic approach. However, only 5 to 25% of patients with pancreatic cancer are suitable for resection at the time of diagnosis ([@b19-ol-06-02-0521]).

With recent developments in molecular biology techniques and following the mapping of the entire human genome, gene therapy for pancreatic cancer is becoming available. It has been reported that DLC-1 is expressed in a number of normal human tissues and is downregulated or absent in various types of human cancer ([@b9-ol-06-02-0521]--[@b11-ol-06-02-0521]). Reduced mRNA levels have also been observed in certain tumor cell lines ([@b15-ol-06-02-0521],[@b20-ol-06-02-0521],[@b21-ol-06-02-0521]). These results suggest that DLC-1 may function as a tumor suppressor.

In the present study, the overexpression of the DLC-1 gene in the PANC-1 cell line resulted in the inhibition of cell growth *in vitro*. This result is consistent with other studies. Wong *et al* showed that the overexpression of DLC-1 in SMMC-7721 human HCC cells that lack endogenous DLC-1 expression was able to inhibit cell proliferation and invasiveness ([@b5-ol-06-02-0521]). In addition, Healy *et al* observed that the restoration of DLC-1 expression in non-small cell lung cancer cell lines impaired anchorage-dependent and -independent growth, as well as invasion *in vitro* ([@b22-ol-06-02-0521]). It was demonstrated that the suppressive function may be attributable to the biological functions of the DLC-1 gene, which include the organization of the cytoskeleton, the formation of focal adhesions and the induction of apoptosis ([@b4-ol-06-02-0521],[@b17-ol-06-02-0521],[@b23-ol-06-02-0521]).

Liposome-mediated intravenous gene delivery in animals usually results in expression in the major organs, including the lung, kidney, spleen and liver, and is not associated with autoimmunity and toxicity ([@b24-ol-06-02-0521]). Transgenes have continued to be expressed in large numbers of cells in multiple tissues for at least nine weeks without any apparent treatment-related toxicity following a single intravenous injection of liposome:plasmid complexes ([@b25-ol-06-02-0521]). Chen *et al* noted that i.v. injections of liposomes complexed to PCI-endostatin inhibited the growth of MDA-MB-435 tumors implanted in the mammary fat pads of nude mice by ∼40% compared with either empty vector (PCI) or untreated controls ([@b26-ol-06-02-0521]).

Thus, this method of gene transfer may be appropriate for human gene therapy. In the present study, it was observed that liposome:DNA complexes administered intravenously decreased the growth of subcutaneously-inoculated tumors, demonstrating that DLC-1 had an effect on tumorigenicity *in vivo*, which is a result supported by other studies ([@b16-ol-06-02-0521],[@b17-ol-06-02-0521]).

In summary, in the present study, the overexpression of the DLC-1 gene in the PANC-1 cells inhibited cell proliferation, suggesting that the DLC-1 gene maybe be a tumor suppressor for pancreatic cancer. The results of this experiment suggested that the DLC-1 gene may be a promising target in gene therapy for pancreatic cancer. The present study also provides experimental evidence for further research into gene therapy for pancreatic cancer.

![RT-PCR analysis for the presence of the DLC-1 gene in the PANC-1 cell line. M, marker; lane 1, untransfected cells; lane 2, empty vector-transfected cells; lane 3, pcDNA3.1(+)/DLC-1-transfected cell. β-actin was analyzed as a positive control. The expression of mRNA was upregulated in the pcDNA3.1(+)/DLC-1 transfected cells.](OL-06-02-0521-g00){#f1-ol-06-02-0521}

![Western blot analysis of DLC-1 protein in the PANC-1 cell line. Lane 1, untransfected cells; lane 2, empty vector-transfected cells; lane 3, pcDNA3.1(+)/DLC-1-transfected cells. Weak bands were detected in the empty vector-transfected and untransfected cells. The molecular size of DLC-1 is 123 kDa; β-actin is 42 kDa.](OL-06-02-0521-g01){#f2-ol-06-02-0521}

![MTT assay for the assessment of cell proliferation in the PANC-1 cell line. OD values were measured in each group (untransfected, empty vector and pcDNA3.1(+)/DLC-1). Significant growth inhibition was observed. ^\*^P\<0.05 vs. untransfected; ^\*\*^P\<0.05 vs. empty vector.](OL-06-02-0521-g02){#f3-ol-06-02-0521}

![Injection of liposome:DNA complexes into athymic nude mice bearing PANC-1 tumors. Tumor volume (mm^3^) was measured in all groups at each treatment injection time. By the fifth injection, the liposome:pcDNA3.1(+)/DLC-1 was statistically different from the liposome:pcDNA3.1(+) and isosmotic saline treatment groups (^\*^P\<0.05).](OL-06-02-0521-g03){#f4-ol-06-02-0521}
